The first clinical tests of a bionic eye are likely within two years and commercialization within five, according to researchers.
A bionic eye is a form of neural prosthesis intended to partially restore lost vision or amplify existing vision.
There is a lot of promising research being done right now. We are living in a very exciting time.
However, we can't put our plans and dreams on hold until this research delivers a cure.
I will never forget the day that I discovered a Telesensory video magnifier in a university library. It was 1977. I was just about to drop out of college before I made this discovery.
That video magnifier made it possible for me to complete college and live my dream as a public school teacher for 21 years!
Today I am very proud to own Amazing Video Magnifiers where I distribute only Telesensory video magnifiers.
They are, in my opinion, the most reliable and cost efficient.
I encourage you to visit the site and read about the various outstanding units.
Saturday, May 30, 2009
Sunday, May 10, 2009
New Medical Study Establishes First-Ever Long-Term Benefits for Macular Degeneration Sufferers Using Macular Health Vitamin Supplement
New Medical Study Establishes First-Ever Long-Term Benefits for Macular Degeneration Sufferers Using Macular Health Vitamin Supplement
Eye disease product has the potential to preserve vision for millions
BIRMINGHAM, Ala., April 28 /PRNewswire/ -- As many as 17.8 million people will suffer from age-related macular degeneration (AMD) by 2050 and 1.57 million will be blind from the disease, according to the U.S. Centers for Disease Control and Prevention. However, a new medical study by a group of retina specialists at the Callahan Eye Foundation Hospital at the University of Alabama Birmingham (UAB) indicates that with the use of the Macular Health vitamin supplement there is a way to reduce these numbers and potentially preserve the vision of millions.
The second phase of the Multifocal Electroretinogram (MERG) study recently revealed that patients suffering from AMD experienced long-term benefits from taking Macular Health, a special combination of supplemental vitamins, minerals and carotenoids. Phase I of the MERG study, completed in 2005, confirmed an average of 16 percent improvement in vision after taking Macular Health for only 12 weeks. Phase II measured the vision function of the same patients two years later and found an average improvement in vision of 17 percent.
"The outcome of this study is extremely encouraging for sufferers of age-related macular degeneration," says John O. Mason, III, MD, researcher and retinal specialist at the Callahan Eye Foundation Hospital. "These new findings prove that Macular Health can slow vision loss and actually improve vision function over time."
MERG testing was used to gauge the vision of AMD patients before and after using the Macular Health supplement. The test results of patients taking Macular Health were compared to results of a control group that did not take the supplement. Phase II of the study was accepted by the Association for Research and Vision in Ophthalmology (ARVO) for poster presentation. Mason and a team of retina specialists will continue to monitor study participants to evaluate improvement in eye health and vision with the use of Macular Health.
Jeffery McAnnally, President of Macular Health, LLC, says, "On behalf of the Macular Health Company, I am pleased to share this additional proof of Macular Health's effectiveness. Not only is Macular Health the most affordable product of its kind on the market today, it is the easiest to take."
An estimated 9 million people currently suffer from AMD, and one-third of adults over 70 are afflicted with this incurable disease. AMD is the leading cause of blindness in Americans 50 years of age and older. AMD is a breakdown of the macula of the eye that typically occurs during the aging process. Damage of the macula increases the difficulty of seeing fine details and even faces clearly.
To learn more about age-related macular degeneration or the Macular Health vitamin supplement, visit www.macularhealth.com. To speak with John O. Mason, III, MD, please contact Julie Ward at 205.503.5955 or julie@styleadvertising.com.
Website: http://www.macularhealth.com/
Eye disease product has the potential to preserve vision for millions
BIRMINGHAM, Ala., April 28 /PRNewswire/ -- As many as 17.8 million people will suffer from age-related macular degeneration (AMD) by 2050 and 1.57 million will be blind from the disease, according to the U.S. Centers for Disease Control and Prevention. However, a new medical study by a group of retina specialists at the Callahan Eye Foundation Hospital at the University of Alabama Birmingham (UAB) indicates that with the use of the Macular Health vitamin supplement there is a way to reduce these numbers and potentially preserve the vision of millions.
The second phase of the Multifocal Electroretinogram (MERG) study recently revealed that patients suffering from AMD experienced long-term benefits from taking Macular Health, a special combination of supplemental vitamins, minerals and carotenoids. Phase I of the MERG study, completed in 2005, confirmed an average of 16 percent improvement in vision after taking Macular Health for only 12 weeks. Phase II measured the vision function of the same patients two years later and found an average improvement in vision of 17 percent.
"The outcome of this study is extremely encouraging for sufferers of age-related macular degeneration," says John O. Mason, III, MD, researcher and retinal specialist at the Callahan Eye Foundation Hospital. "These new findings prove that Macular Health can slow vision loss and actually improve vision function over time."
MERG testing was used to gauge the vision of AMD patients before and after using the Macular Health supplement. The test results of patients taking Macular Health were compared to results of a control group that did not take the supplement. Phase II of the study was accepted by the Association for Research and Vision in Ophthalmology (ARVO) for poster presentation. Mason and a team of retina specialists will continue to monitor study participants to evaluate improvement in eye health and vision with the use of Macular Health.
Jeffery McAnnally, President of Macular Health, LLC, says, "On behalf of the Macular Health Company, I am pleased to share this additional proof of Macular Health's effectiveness. Not only is Macular Health the most affordable product of its kind on the market today, it is the easiest to take."
An estimated 9 million people currently suffer from AMD, and one-third of adults over 70 are afflicted with this incurable disease. AMD is the leading cause of blindness in Americans 50 years of age and older. AMD is a breakdown of the macula of the eye that typically occurs during the aging process. Damage of the macula increases the difficulty of seeing fine details and even faces clearly.
To learn more about age-related macular degeneration or the Macular Health vitamin supplement, visit www.macularhealth.com. To speak with John O. Mason, III, MD, please contact Julie Ward at 205.503.5955 or julie@styleadvertising.com.
Website: http://www.macularhealth.com/
Sunday, May 3, 2009
Possible Cure on Horizon
It's a sight for sore eyes.
Stem cell therapy to cure blindness is being developed by British scientists, and surgeons believe it could become a simple procedure that will be available in six or seven years' time, the London Times reported.
The process involves replacing a layer of dying cells with fresh ones created from embryonic stem cells.
It targets age-related macular degeneration (AMD), one of the most common causes of blindness, which involves the loss of eye cells.
"This is a huge step forward for patients," Tom Bremridge, chief executive of the Macular Disease Society, told the Times. "We are extremely pleased that the big guns have become involved, because, once this treatment is validated, it will be made available to a huge volume of patients."
Embryonic stem cells have the ability to develop into all types of body tissue.
Their use is controversial, however, because it involves the destruction of human embryos.
Lab tests done by the British team have shown that stem cells can prevent blindness in rats, and similar elements work on pigs.
A clinical trial is expected within two years.
It will most likely be the second in the world to use embryonic stem cells on humans. The first, spinal cord injury sufferers, will start later this year in the United States.
Stem cell therapy to cure blindness is being developed by British scientists, and surgeons believe it could become a simple procedure that will be available in six or seven years' time, the London Times reported.
The process involves replacing a layer of dying cells with fresh ones created from embryonic stem cells.
It targets age-related macular degeneration (AMD), one of the most common causes of blindness, which involves the loss of eye cells.
"This is a huge step forward for patients," Tom Bremridge, chief executive of the Macular Disease Society, told the Times. "We are extremely pleased that the big guns have become involved, because, once this treatment is validated, it will be made available to a huge volume of patients."
Embryonic stem cells have the ability to develop into all types of body tissue.
Their use is controversial, however, because it involves the destruction of human embryos.
Lab tests done by the British team have shown that stem cells can prevent blindness in rats, and similar elements work on pigs.
A clinical trial is expected within two years.
It will most likely be the second in the world to use embryonic stem cells on humans. The first, spinal cord injury sufferers, will start later this year in the United States.
Subscribe to:
Posts (Atom)
